Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Posts Fallen Revenue, Swollen Net Loss in Q3

NEW YORK, Oct. 31 - Transgenomic reported a decrease in third-quarter revenue, increased R&D spending, and a widened net loss.

 

For the three months ended Sept. 30, the company posted $9.1 million in revenue, an 11-percent drop-off compared with $10.3 million in the same quarter one year ago.

 

R&D spending in the quarter increased to $3.2 million from $2.2 million year over year, Transgenomic said.

 

As a result, third-quarter net loss blossomed to $4.7 million, or $.20 per share, from $1.9 million, or $.08 per share one year ago.

 

CEO Collin D'Silva said he has "confidence" that Transgenomics' instruments business "will regain its past momentum" next year. "We are optimistic about our opportunities to advance [the] Wave technology into higher-value markets such as molecular diagnostics and theranostic applications in oncology," he said.

 

Transgenomic said it had around $18.4 million in cash, cash equivalents, and short-term investments as of Sept. 30.

 

Click here for more information.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.